Several HSPA5-targeting therapeutic modalities are under investigation, including the human IgM antibody PAT-SM6, which has shown promising results in combination therapies for R/R MM, both in vitro and in vivo [51, 52]. The gene discussed is CD40LG; the disease is Miyoshi myopathy.